Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.
The details can be read here.
1 comment:
It will be interested to see this company entering the US market with such innovative products - As a diabetic patient, I will have no problem to take such friendly oral insulin treatment even if my insurance does not cover it!
Post a Comment